26 May 2021 | 09:20am
StockMarketWire.com - Property investor Panther Securities swung to a full-year profit, thanks to positive movements in the value of its investment properties.
Pre-tax profit for the year through December amounted to £2.6 million, compared to year-on-year losses of £5.0 million.
Rental revenue fell to £13.1 million, down from £14.2 million.
Panther Securities proposed a final dividend of 6p per share, adding to an interim dividend of 6p. I am pleased that I am able to present the results for the year ended 31 December 2020, which, by anybody s view, has been a most unusual year, chairman Andrew Perloff said.
At 9:20am: [LON:PNS] Panther Securities PLC share price was 0p at 175p
30 April 2021 | 07:54am
StockMarketWire.com - Clinical AI company Sensyne Health has signed a five year non-exclusive Strategic Research Agreement (SRA) with the Royal Devon and Exeter NHS Foundation Trust.
The agreement will enable the ethical application of clinical AI research to improve patient care and accelerate research into new medicines. The RD&E dataset covers 1.2 million unique patient records, with 110,000 annual hospital admissions (2019/20) from a patient population of approximately 450,000 people.
The Trust will receive 1,428,571 ordinary shares in Sensyne Health plc representing 0.87% of the existing issued share capital of Sensyne. This brings the total share ownership held by NHS Trusts in Sensyne to 13.3%.
12 March 2021 | 09:39am
StockMarketWire.com - Clinical AI technology company Sensyne has signed a £470,000 agreement with the Department of Health & Social Care (DHSC) to conduct the second stage of a pilot study of its MagnifEye technology for use with COVID-19 lateral flow diagnostic tests.
The MagnifEye system is a software application available as both a smartphone app and a web application, that uses a cloud-based deep learning algorithm to automate the reading and analysis of different diagnostic tests, including lateral flow tests.
The agreement with the DHSC follows an announcement made by Sensyne on 09 February 2021 that it had signed an exclusive licence and development agreement with Excalibur Healthcare Services Limited to apply MagnifEye for use with lateral flow rapid diagnostic tests.
9 February 2021 | 13:58pm
StockMarketWire.com - Sensyne Health has licenced its MagnifEye technology to Excalibur Healthcare Services for use with lateral flow diagnostic tests, including Covid-19.
The MagnifEye system is a smartphone and a web-based app that uses a cloud-based deep learning algorithm to analyse lateral flow tests.
The initial focus will be on use of MagnifEye for Covid-19 antigen testing, followed by its potential application in new lateral flow diagnostic tests for serology, cancer and other disease conditions that Excalibur is currently developing.
The Excalibur Covid-19 antigen lateral flow diagnostic test has been approved by the UK regulator for mass population screening in symptomatic and asymptomatic people.